Download PDF
Z Orthop Unfall 2015; 153(05): 479-487
DOI: 10.1055/s-0035-1546146
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Das biologische Skalpell II – Frakturheilung und pharmakologische Einflussfaktoren

The Biological Knife II – Fracture Healing and Pharmacological Interactions
P. Garcia
1   Klinik für Unfall-, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Münster
,
J. Everding
1   Klinik für Unfall-, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Münster
,
D. Horn
1   Klinik für Unfall-, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Münster
,
J. H. Holstein
2   Klinik für Unfall-, Hand- und Wiederherstellungschirurgie, Uniklinikum des Saarlandes, Homburg/Saar
,
M. Raschke
1   Klinik für Unfall-, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Münster
› Author Affiliations
Further Information

Publication History

Publication Date:
29 June 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Ursachen für eine gestörte oder ausbleibende Frakturheilung sind multifaktoriell. Neben mechanischen Ursachen kommt den biologischen Einflussfaktoren eine große Rolle zu. Da uns kaum Therapieansätze zur Stimulation der Frakturheilung zur Verfügung stehen, sollte die Optimierung der biologischen Grundvoraussetzungen essenzieller Bestandteil der Frakturbehandlung sein. Neben der Beachtung patientenbezogener Einflussfaktoren können auch verschiedene Medikamente die Frakturheilung positiv oder negativ beeinflussen. Bei jüngeren, ansonsten gesunden Patienten erfolgt im Rahmen der Frakturbehandlung regelhaft eine Medikation mit Arzneistoffen zur Schmerztherapie und zur Prophylaxe von Infektionen und Thrombosen. Bei vielen älteren Patienten liegt zusätzlich aufgrund bestehender Komorbiditäten häufig bereits zum Zeitpunkt der Fraktur eine Polymedikation mit unterschiedlichsten Arzneistoffen vor. Ziel der vorliegenden Arbeit ist es, eine Übersicht zu geben über pharmakologische Einflussfaktoren auf die Frakturheilung. Die Kenntnis dieser Einflussfaktoren ermöglicht es, durch Vermeidung bestimmter Arzneistoffe die Bedingungen für eine zeitgerechte Frakturheilung zu optimieren. Darüber hinaus soll ein Überblick gegeben werden, welche pharmakologischen Wirkstoffe aktuell oder in naher Zukunft zur Verfügung stehen, um die Frakturheilung zu stimulieren.

Abstract

The reasons for delayed fracture healing or non-union formation are multifactorial. Mechanical factors are well known to influence the process of fracture healing. However, there is a lack of knowledge about the biological conditions that have to be achieved for adequate bone healing. Treatment of non-unions is still demanding and we have only poor options to stimulate the bone healing process. Therefore, it is important to optimise the biological conditions to avoid non-union formation. Beside patient-related factors, pharmacological drugs are able to impede or stimulate fracture healing. Especially geriatric patients show a pre-existing drug medication due to different co-morbidities. However, also younger patients are frequently treated with different drugs for infection prophylaxis, analgesia or thrombosis prophylaxis. The aim of the current review article is to give an overview about the influence of different pharmacological agents on the process of fracture healing. A deeper understanding of a drug-related influence on fracture healing could help the medical practitioner to optimise the general conditions for adequate fracture healing, i.e., by avoiding specific pharmacological agents. Vice versa some drugs could be used to stimulate fracture healing in the future.

Schlüsselwörter

Frakturheilung - Biologie - Medikamente - Knochenheilung - Osteoporose

Key words

fracture healing - biology - drugs - bone healing - osteoporosis
 

  • Literatur

  • 1 Matos MA, Tannuri U, Guarniero R. The effect of zoledronate during bone healing. J Orthop Traumatol 2010; 11: 7-12
    CrossrefPubMedGoogle Scholar
  • 2 Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-1809
    CrossrefPubMedGoogle Scholar
  • 3 Solomon DH, Hochberg MC, Mogun H et al. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int 2009; 20: 895-901
    CrossrefPubMedGoogle Scholar
  • 4 Rozental TD, Vazquez MA, Chacko AT et al. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg 2009; 34: 595-602
    CrossrefPubMedGoogle Scholar
  • 5 Goldhahn J, Little D, Mitchell P et al. Evidence for anti-osteoporosis therapy in acute fracture situations–recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. Bone 2010; 46: 267-271
    CrossrefPubMedGoogle Scholar
  • 6 Gong HS, Song CH, Lee YH et al. Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures. J Bone Joint Surg Am 2012; 94: 1729-1736
    CrossrefPubMedGoogle Scholar
  • 7 Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1–34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999; 14: 960-968
    CrossrefPubMedGoogle Scholar
  • 8 Aspenberg P, Genant HK, Johansson T et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010; 25: 404-414
    CrossrefPubMedGoogle Scholar
  • 9 Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop 2010; 81: 234-236
    CrossrefPubMedGoogle Scholar
  • 10 Peichl P, Holzer LA, Maier R et al. Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 2011; 93: 1583-1587
    CrossrefPubMedGoogle Scholar
  • 11 Alegre DN, Ribeiro C, Sousa C et al. Possible benefits of strontium ranelate in complicated long bone fractures. Rheumatol Int 2012; 32: 439-443
    CrossrefPubMedGoogle Scholar
  • 12 Gerstenfeld LC, Sacks DJ, Pelis M et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009; 24: 196-208
    CrossrefPubMedGoogle Scholar
  • 13 Adami S, Libanati C, Boonen S et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am 2012; 94: 2113-2119
    CrossrefPubMedGoogle Scholar
  • 14 Cao Y, Mori S, Mashiba T et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002; 17: 2237-2246
    CrossrefPubMedGoogle Scholar
  • 15 Goldhahn J, Feron JM, Kanis J et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 2012; 90: 343-353
    CrossrefPubMedGoogle Scholar
  • 16 Lyritis G, Boscainos PJ. Calcitonin effects on cartilage and fracture healing. J Musculoskelet Neuronal Interact 2001; 2: 137-142
    PubMedGoogle Scholar
  • 17 Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006; 24: 581-589
    CrossrefPubMedGoogle Scholar
  • 18 Garcia P, Schwenzer S, Slotta JE et al. Inhibition of angiotensin-converting enzyme stimulates fracture healing and periosteal callus formation – role of a local renin-angiotensin system. Br J Pharmacol 2010; 159: 1672-1680
    CrossrefPubMedGoogle Scholar
  • 19 Graham S, Hammond-Jones D, Gamie Z et al. The effect of beta-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing. Expert Opin Investig Drugs 2008; 17: 1281-1299
    CrossrefPubMedGoogle Scholar
  • 20 Ilic K, Obradovic N, Vujasinovic-Stupar N. The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. Calcif Tissue Int 2013; 92: 217-227
    CrossrefPubMedGoogle Scholar
  • 21 Mundy G, Garrett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-1949
    CrossrefPubMedGoogle Scholar
  • 22 Patil S, Holt G, Raby N et al. Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing. J Orthop Res 2009; 27: 281-285
    CrossrefPubMedGoogle Scholar
  • 23 Nguyen ND, Wang CY, Eisman JA et al. On the association between statin and fracture: a Bayesian consideration. Bone 2007; 40: 813-820
    CrossrefPubMedGoogle Scholar
  • 24 Reid IR, Hague W, Emberson J et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001; 357: 509-512
    CrossrefPubMedGoogle Scholar
  • 25 Toh S, Hernandez-Diaz S. Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf 2007; 16: 627-640
    CrossrefPubMedGoogle Scholar
  • 26 Perry AC, Prpa B, Rouse MS et al. Levofloxacin and trovafloxacin inhibition of experimental fracture-healing. Clin Orthop Relat Res 2003; 414: 95-100
    CrossrefPubMedGoogle Scholar
  • 27 Pountos I, Georgouli T, Blokhuis TJ et al. Pharmacological agents and impairment of fracture healing: what is the evidence?. Injury 2008; 39: 384-394
    CrossrefPubMedGoogle Scholar
  • 28 Kim SG, Chung TY, Kim MS et al. The effect of high local concentrations of antibiotics on demineralized bone induction in rats. J Oral Maxillofac Surg 2004; 62: 708-713
    CrossrefPubMedGoogle Scholar
  • 29 Stinchfield FE, Sankaran B, Samilson R. The effect of anticoagulant therapy on bone repair. J Bone Joint Surg Am 1956; 38-A: 270-282
    PubMedGoogle Scholar
  • 30 Petersen W, Wildemann B, Pufe T et al. The angiogenic peptide pleiotrophin (PTN/HB-GAM) is expressed in fracture healing: an immunohistochemical study in rats. Arch Orthop Trauma Surg 2004; 124: 603-607
    CrossrefPubMedGoogle Scholar
  • 31 Say F, Iltar S, Alemdaroglu KB et al. The effect of various types low molecular weight heparins on fracture healing. Thromb Res 2013; 131: e114-e119
    CrossrefPubMedGoogle Scholar
  • 32 Zhang X, Schwarz EM, Young DA et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109: 1405-1415
    CrossrefPubMedGoogle Scholar
  • 33 Naik AA, Xie C, Zuscik MJ et al. Reduced COX-2 expression in aged mice is associated with impaired fracture healing. J Bone Miner Res 2009; 24: 251-264
    CrossrefPubMedGoogle Scholar
  • 34 Geusens P, Emans PJ, de Jong JJ et al. NSAIDs and fracture healing. Curr Opin Rheumatol 2013; 25: 524-531
    CrossrefPubMedGoogle Scholar
  • 35 Dodwell ER, Latorre JG, Parisini E et al. NSAID exposure and risk of nonunion: a meta-analysis of case-control and cohort studies. Calcif Tissue Int 2010; 87: 193-202
    CrossrefPubMedGoogle Scholar
  • 36 Lack WD, Fredericks D, Petersen E et al. Effect of aspirin on bone healing in a rabbit ulnar osteotomy model. J Bone Joint Surg Am 2013; 95: 488-496
    CrossrefPubMedGoogle Scholar
  • 37 Khalili H, Huang ES, Jacobson BC et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012; 344: e372
    CrossrefPubMedGoogle Scholar
  • 38 Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011; 48: 768-776
    CrossrefPubMedGoogle Scholar
  • 39 Histing T, Stenger D, Scheuer C et al. Pantoprazole, a proton pump inhibitor, delays fracture healing in mice. Calcif Tissue Int 2012; 90: 507-514
    CrossrefPubMedGoogle Scholar
  • 40 Hamzat H, Sun H, Ford JC et al. Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. Drugs Aging 2012; 29: 681-690
    CrossrefPubMedGoogle Scholar
  • 41 Holstein JH, Klein M, Garcia P et al. Rapamycin affects early fracture healing in mice. Br J Pharmacol 2008; 154: 1055-1062
    CrossrefPubMedGoogle Scholar
  • 42 Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-1093
    CrossrefPubMedGoogle Scholar
  • 43 Sarhaddi D, Tchanque-Fossuo CN, Poushanchi B et al. Amifostine protects vascularity and improves union in a model of irradiated mandibular fracture healing. Plast Reconstr Surg 2013; 132: 1542-1549
    CrossrefPubMedGoogle Scholar
  • 44 Gaston MS, Simpson AH. Inhibition of fracture healing. J Bone Joint Surg Br 2007; 89: 1553-1560
    CrossrefPubMedGoogle Scholar
  • 45 Hogevold HE, Grogaard B, Reikeras O. Effects of short-term treatment with corticosteroids and indomethacin on bone healing. A mechanical study of osteotomies in rats. Acta Orthop Scand 1992; 63: 607-611
    PubMedGoogle Scholar
  • 46 Holstein JH, Menger MD, Scheuer C et al. Erythropoietin (EPO): EPO-receptor signaling improves early endochondral ossification and mechanical strength in fracture healing. Life Sci 2007; 80: 893-900
    CrossrefPubMedGoogle Scholar
  • 47 Garcia P, Speidel V, Scheuer C et al. Low dose erythropoietin stimulates bone healing in mice. J Orthop Res 2011; 29: 165-172
    CrossrefPubMedGoogle Scholar
  • 48 Bakhshi H, Kazemian G, Emami M et al. Local erythropoietin injection in tibiofibular fracture healing. Trauma Mon 2013; 17: 386-388
    PubMedGoogle Scholar
  • 49 Raschke M, Kolbeck S, Bail H et al. Homologous growth hormone accelerates healing of segmental bone defects. Bone 2001; 29: 368-373
    CrossrefPubMedGoogle Scholar
  • 50 Van der Lely AJ, Lamberts SW, Jauch KW et al. Use of human GH in elderly patients with accidental hip fracture. Eur J Endocrinol 2000; 143: 585-592
    CrossrefPubMedGoogle Scholar
  • 51 Boonen S, Rosen C, Bouillon R et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab 2002; 87: 1593-1599
    CrossrefPubMedGoogle Scholar
  • 52 Raschke M, Rasmussen MH, Govender S et al. Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial. Eur J Endocrinol 2007; 156: 341-351
    CrossrefPubMedGoogle Scholar
  • 53 Govender S, Csimma C, Genant HK et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002; 84-A: 2123-2134
    PubMedGoogle Scholar
  • 54 Burkus JK, Gornet MF, Dickman CA et al. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 2002; 15: 337-349
    CrossrefPubMedGoogle Scholar
  • 55 Friedlaender GE, Perry CR, Cole JD et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001; 83-A (Suppl. 01) S151-S158
    PubMedGoogle Scholar
  • 56 Garrison KR, Shemilt I, Donell S et al. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 2010; (6) CD006950
    PubMedGoogle Scholar
  • 57 Carreira AC, Lojudice FH, Halcsik E et al. Bone morphogenetic proteins: facts, challenges, and future perspectives. J Dent Res 2014; 93: 335-345
    CrossrefPubMedGoogle Scholar
  • 58 Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013; 19: 179-192
    CrossrefPubMedGoogle Scholar
  • 59 Padhi D, Jang G, Stouch B et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26: 19-26
    CrossrefPubMedGoogle Scholar
  • 60 McClung MR, Grauer A, Boonen S et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370: 412-420
    CrossrefPubMedGoogle Scholar
  • 61 Calori GM, Phillips M, Jeetle S et al. Classification of non-union: need for a new scoring system?. Injury 2008; 39 (Suppl. 02) S59-S63
    CrossrefPubMedGoogle Scholar